Table 4 Polymorphisms and toxicity due to treatment of colorectal cancer patients
From: Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival
Polymorphism | Toxicity, n (%) | p |
|---|---|---|
ERCC1-rs11615 | Stomatitisa | |
T/T | 14/70 (20.0) | |
C/T + C/C | 8/94 (8.5) | 0.03 |
ERCC1-rs11615 | Nausea | |
T/T | 24/37 (64.9) | |
C/T + C/C | 48/58 (82.8) | 0.04 |
ERCC2-rs13181 | Eye reactions | |
A/A | 7/37 (18.9) | |
A/C + C/C | 27/58 (46.6) | 0.006 |
ERCC2-rs13181 | Thrombocytopenia | |
A/A | 8/36 (22.2) | |
A/C + C/C | 31/59 (52.5) | 0.004 |
ERCC2-rs238406 | Thrombocytopenia | |
C/C | 16/28 (57.1) | |
C/A + A/A | 23/67 (34.3) | 0.03 |
ERCC2-rs13181 | Dose reduction/discontinuationa | |
A/A | 38/70 (54.3) | |
A/C + C/C | 69/96 (71.9) | 0.02 |